ClinicalTrials.gg
TerminatedNCT01972854Updated Apr 26, 2021

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

A Phase 3 interventional study of riboflavin solution and placebo solution in Keratoconus, sponsored by Glaukos Corporation. Terminated at 11 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-04-26.

Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.

Enrollment
18th of 23
92 · median 170
Started
2013
the only one that year
Phase 3
12 of 23
3 open now
Registered
13th of 23
by date
Lead sponsor
3 of 23
Glaukos Corporation

Among the 23 studies testing riboflavin in Keratoconus, this one is the 18th largest by enrollment, is the only one that started in 2013, is one of 12 in phase 3, and was the 13th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About riboflavin

Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing riboflavin in Keratoconus, or all of them as a file.
02

Study summary

The objectives of this study are to evaluate the safety and efficacy of corneal collagen cross-linking performed with VibeX (riboflavin ophthalmic solution) and the KXL System as compared to placebo in impeding the progression of, and/or reducing, maximum corneal curvature.

03

Conditions studied

  • Keratoconus

Browse trials for

Keywords

  • keratoconus
  • cross-linking
  • KXL
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria in order to be enrolled in the trial:

  1. Be at least 12 years of age, male or female, of any race;
  2. Provide written and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well as having a parent or legal guardian sign an informed consent;
  3. Willingness and ability to follow all instructions and comply with schedule for follow-up visits, including the ability to read English to complete the NEI-VFQ 25 questionnaire;
  4. For females capable of becoming pregnant, agree to have urine pregnancy testing performed at Visit 2 prior to randomization of the study eye and prior to treatment of a fellow and/or cross-over eye; must not be lactating, and must agree to use a medically acceptable form of for at least one week prior to Visit 2, one week prior to treatment of a fellow eye or cross-over eye, and continue to use the method for one month following the last treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  5. Subjects > 25 years old at the time of screening of their study eye must meet the following criteria. Subjects ≤ 25 years old and all subjects who have their fellow-eye or crossover eye treated are not required to meet these criteria;

    • Having a diagnosis of progressive keratoconus defined as one or more of the following changes over a period of 36 months or less:
    1. An increase of ≥ 1.00 D in the steepest keratometry value (ksteep)
    2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest refraction or as evaluated by comparing eyeglass or contact lens prescriptions to current subjective manifest refraction
    3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D in subjective manifest refraction or as evaluated by comparing eyeglass or contact lens prescriptions to current subjective manifest refraction
    4. A decrease ≥ 0.1 mm in the BOZR (Back Optical Zone Radius) in rigid contact lens wearers where other information is not available
  6. Having topographic evidence of keratoconus with a diagnosis of mild, moderate, or severe keratoconus defined as the following:

    • Mild Keratoconus:

      1. Axial topography consistent with keratoconus
      2. Flat Pentacam keratometry reading ≤ 51.00D
    • Moderate Keratoconus:

      1. Axial topography consistent with keratoconus
      2. Flat Pentacam keratometry reading > 51.00 D and ≤ 56.00 D or astigmatism ≥ 8.00 D
    • Severe Keratoconus:

      1. Axial topography consistent with keratoconus with marked areas of steepening
      2. Flat Pentacam keratometry reading > 56.00 D
  7. Presence of central or inferior steepening on the Pentacam map;
  8. Have a maximum corneal curvature, as measured by Kmax, of ≥ 47.00 D;
  9. BSCVA of ≥ 1 letter and ≤ 80 letters on ETDRS chart;
  10. Contact Lens Wearers Only: Removal of contact lenses is required for a 1 week period prior to the first screening refraction visit (and each subsequent Visit 1, as necessary) and must remain out until the 1 month visit is completed;
  11. Contact Lens Wearers Only: Manifest refraction must be stable between two consecutive visits which occur at least 7 days apart. A stable refraction is one in which the manifest refraction spherical equivalent and the average K (Km) on the Pentacam taken at the first visit do not differ by more than 0.75 D from the respective measurements taken at the second exam. A contact lens wearer is defined as someone who has worn contact lenses in the eye to be treated in the last 30 days.

Exclusion criteria

Exclusion Criteria:

Subjects must not meet any of the following criteria to be enrolled in the trial:

  1. , sensitivity or known allergy to the use of the test article(s) or their components;
  2. If female, be pregnant, nursing or planning a pregnancy during the course of the study or have a positive urine pregnancy test at Visit 2 prior to randomization or treatment of either eye;
  3. Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme;
  4. A history of previous corneal surgery or the insertion of Intacs in the eye to be treated;
  5. A history of previous Limbal Relaxing Incision (LRI) procedure in the eye to be treated;
  6. Corneal pachymetry that is \< 375 microns prior to epithelial debridement at the thinnest point measured by Pentacam in the eye to be treated;
  7. Eyes which are aphakic;
  8. Eyes which are pseudophakic and do not have a UV blocking lens implanted;
  9. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications. For example:

    1. History or evidence of active or inactive corneal disease (e.g., herpes simplex keratitis, herpes zoster keratitis, corneal melt, recurrent corneal erosion syndrome, corneal dystrophy, etc.);
    2. corneal scarring in the cross-linking treatment zone that is not related to keratoconus or, in the investigator's opinion, will interfere with the cross-linking procedure;
  10. A history of delayed epithelial healing in the eye to be treated;
  11. Subjects with nystagmus or any other condition that would prevent a steady gaze during the treatment or other diagnostic tests;
  12. Subjects with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing;
  13. Taking supplements containing Vitamin C (ascorbic acid) within 1 week of the cross-linking treatment;
  14. A history of previous corneal crosslinking treatment in the eye to be treated;
  15. The subject should not have participated in any drug or device study within 30 days of screening or be concurrently enrolled in another investigational drug or device study.
  16. The Investigator may exclude or discontinue any subject for any sound medical reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    riboflavin solution and KXL System

    The cornea will receive 5 drops of VibeX (0.12% riboflavin ophthalmic solution). Five additional VibeX drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.

    Drug: riboflavin solution · Device: KXL System

  • Placebo comparator
    placebo solution and KXL System

    The cornea will receive 5 drops of placebo (0.0% riboflavin ophthalmic solution. Five additional placebo drops will be instilled every two minutes for 20 minutes. The eye will be irradiated for 8 minutes with an on/off cycle of 1 second UVA on/1 second UVA off.

    Drug: placebo solution · Device: KXL System

Interventions

  • 0.12% riboflavin ophthalmic solution

    Also known as: VibeX

  • Drugplacebo solution

    0.0% riboflavin ophthalmic solution

    Also known as: placebo

  • DeviceKXL System

    30mW/cm2

    Also known as: UVA Irradiation

06

What researchers measure

Primary outcomes

  1. Change in Kmax from baseline

    The primary endpoint is the mean change from baseline to 12 months in maximum corneal curvature (Kmax) between the VibeX treatment group and the Placebo control group.

    Time frame: 12 months

07

Study locations

11 sites
  • UC Irvine Department of Ophthalmology
    Irvine, California 92868, United States
  • Gordon -Weiss Vision Institute
    San Diego, California 92122, United States
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
  • Durrie Vision
    Overland Park, Kansas 66211, United States
  • Ophthalmic Consultants of Boston
    Waltham, Massachusetts 02451, United States
  • Hersh Vision Group
    Teaneck, New Jersey 07666, United States
  • UPMC Eye Center
    Pittsburgh, Pennsylvania 15213, United States
  • Vance Thompson Vision
    Sioux Falls, South Dakota 57105, United States
  • Focal Point Vision
    San Antonio, Texas 78229, United States
  • Hoopes Vision
    Draper, Utah 84020, United States
  • See Clearly Vision
    McLean, Virginia 22102, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Mar 2016 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2013
First posted
Oct 31, 2013
Start
Nov 2013
Primary completionActual
Mar 2016
CompletionActual
Apr 2017
Results delay requested
Jun 27, 2016
Last update
Apr 26, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01972854
Responsible party
Sponsor
First posted
Oct 31, 2013
Start date
Nov 2013
Primary completion
Mar 2016
Completion
Apr 2017
Last update
Apr 26, 2021

Study contacts

Peter Hersh, M.D.
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion